2025Q3 业绩稳中有升，加速推进全球化战略 —易实精密（920221.BJ）公司事件点评报告 2026 年 01 月 08 日 买入(维持) 事件 | | | | 基本数据 | 2026-01-07 | | --- | --- | | 当前股价（元） | 17.38 | | 总市值（亿元） | 20 | | 总股本（百万股） | 116 | | 流通股本（百万股） | 62 | | 52 周价格范围（元） | 14.46-26.71 | | 日均成交额（百万元） | 67.83 | 市场表现 -20 0 20 40 60 80 100 120 (%) 易实精密 沪深300 资料来源：Wind，华鑫证券研究 相关研究 公司 2025Q3 营收 0.86 亿元，同比+8.12%；归母净利润 0.14 亿元，同比+2.28%，主业稳步增长。同时，公司拟对其德国 全资子公司 EC Precision (Germany) GmbH 增加投资总额， 本次增加投资额不超过 790 万欧元，加速推进全球化布局。 投资要点 ▌ 业绩稳健增长，盈利能力保持稳定 营业收入稳步上升，整体业绩符合预期。2025Q3 实现营业收 入 ...

中国上市公司网 近日，易实精密发布公告称，为推进海外战略布局、提升发展能级、扩大国际市场份额并强化竞争优 势，公司计划通过全资子公司易实集团有限公司(以下简称"易实集团")对其全资子公司EC Precision (Germany) GmbH(以下简称"ECPG")增加投资总额,本次增加投资额不超过790万欧元,本次增加投资额的 路径为,公司对易实集团增加投资额,再由易实集团对ECPG增加投资额。公司将根据ECPG的资金需求逐 步增加投入。本次增加投资额前,易实集团注册资本1万港币,公司持股100%,增加投资额后,易实集团注册 资本不变,公司仍然持股100%,若本次拟增加投资额全部完成,公司对易实集团投资额将增加790万欧元。 本次增加投资额前,ECPG注册资本25,000欧元,易实集团持股100%,增加投资额后,ECPG注册资本不变,若 本次拟增加投资额全部完成,易实集团对ECPG的投资总额将增加790万欧元,易实集团持股100%。 作为易实精密的香港全资子公司，易实集团主要承担海外业务统筹职能。其注册地址位于香港九龙湾宏 光道1号亿京中心A座10楼B室，注册资本1万港币，业务性质为控股管理。ECPG为易实精 ...

Economic Overview - In the first half of 2025, China's economy demonstrated strong resilience with a GDP growth of 5.3% year-on-year, supported by consumption contributing 52.3% to economic growth [2][7][8] - The second quarter GDP growth was 5.2% year-on-year and 1.1% quarter-on-quarter, indicating a steady progress in economic performance [2][7] - The GDP deflator index has been negative for nine consecutive quarters, with a value of -1.0% in Q2 2025, while CPI turned positive for the first time in four months at +0.1% in June [2][7][8] Pharmaceutical Sector China Biologic Products (01177.HK) - The company announced a $500 million acquisition of 95.09% of Shanghai Lixin Pharmaceutical, which will enhance its core competitiveness in the oncology field through Lixin's differentiated dual-antibody and ADC technology platforms [10][11][13] - The acquisition is expected to significantly boost the company's capabilities in developing innovative drugs, with several promising candidates in clinical trials [12][13] Sinovac Biotech (688136.SH) - The company has established multiple leading technology platforms for innovative drug development, focusing on oncology and degenerative diseases, which are expected to enhance its valuation [15][16] - The innovative pipeline includes promising candidates that are anticipated to provide new valuation flexibility for the company [17][18] Precision Manufacturing Sector Easy Precision (836221.BJ) - The company reported a revenue of 80 million yuan and a net profit of 15.04 million yuan in Q1 2025, with a focus on precision metal components for the automotive industry [20][21] - Easy Precision is expanding its product line through strategic partnerships and is set to launch a third-generation welding ring production line in 2025, enhancing its market competitiveness [21][22] - The company plans to acquire a 51% stake in Tongyihe to enhance its precision stamping capabilities and drive the localization of harmonic reducer components [23][25]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company is focusing on expanding its customer base in the field of air suspension and enhancing its precision stamping technology to promote the localization of reducer flexible wheels [5] - In Q1 2025, the company achieved revenue of 80 million yuan and a net profit attributable to shareholders of 15.04 million yuan [6] - The company has established itself as a supplier for well-known automotive parts manufacturers, including Tyco Electronics and Bosch [6] - The company signed a strategic cooperation agreement with Konghui Technology to broaden its product line and is expected to achieve mass production of the third-generation welding ring line in 2025 [6][9] - The company plans to acquire 51% of Tongyihe Precision Technology to enhance its development and manufacturing capabilities in precision stamping [6][9] - The establishment of a joint venture in Slovenia aims to enhance overseas layout and local supply capabilities [6][9] Financial Summary - The company forecasts revenue growth from 276 million yuan in 2023 to 609 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 22.91% [8] - The net profit attributable to shareholders is projected to increase from 52 million yuan in 2023 to 100 million yuan in 2027, reflecting a CAGR of 25.37% [8] - The earnings per share (EPS) is expected to rise from 0.44 yuan in 2023 to 0.86 yuan in 2027 [8] - The company maintains a healthy return on equity (ROE), projected to reach 23.54% by 2027 [8]